Seven species (and one cultivated variety) of Hymenocallis (Amaryllidaceae) and the related Pancratium maritima, representing a broad geographical selection, were investigated as sources of pancratistatin [1] now undergoing preclinical development as an anticancer agent. Pancratistatin [1] was found to be a constituent of H. speciosa (Singapore), H. variegated (Singapore), H. pedalis (Seychelles), H. expansa (Bermuda), H. sonoranensis (Mexico), and P. maritimum (Israel). Only two species of Hymenocallis failed to yield one or more of the related cell-growth inhibitory isocarbostyrils such as narciclasine [3a], 7-deoxynarciclasine [3b], and 7-deoxy-trans-dihydronarciclasine [2].